Abstract #560
Key Messages:
- Subcutaneous (SC) injection of peripheral blood mononuclear cells (PBMC) loaded for 4hrs with CD3-directed lentivector (LV) generate a novel CAR T and NK-like (TaNK) cell capable of enhanced proliferation and target elimination
- Following SC administration, CAR expression and expansion initiates at the site of injection from tertiary lymphoid structures comprised of T cells, macrophages, and dendritic cells
- CARpos cells formed subcutaneously effectively traffic to the tumor site within 2 weeks post-injection
- From this novel LV CAR and Driver vector platform, CD19 or CD22 CARpos cells with a T and NK-like phenotype (CD3posCD8posCD56posNKG2Dpos) and unique cytokine profile, mediate target elimination with enhanced systemic proliferation and engraftment compared to traditional CD4/8 41BB CAR-Ts administered intravenously into a lymphoreplete animal model
- Through a subcutaneous initiation from TLS, a rapid and scalable process for the development of a CAR-TaNK therapy with reduced cytokine impact and immunosuppression may be clinically feasible
